^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA G1049R + AKT1 E17K

    i
    Other names: AKT1, AKT, PKB, PRKBA, RAC, V-akt murine thymoma viral oncogene homolog 1, PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns
    Entrez ID:
    5290; 207
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    almost4years
    [VIRTUAL] The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib (ESMO 2020)
    Legal entity responsible for the study: The authors. Funding: Has not received any funding.
    Clinical
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • GNAS (GNAS Complex Locus)
    |
    BRAF V600E • PIK3CA mutation • BRAF V600 • PIK3CA H1047R • IDH1 R132C • BRAF G466V • BRAF G466V + KIT K509Q • GNAS R201C • PIK3CA G1049R + AKT1 E17K • BRAF K601
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)